WASHINGTON, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

        Date of report (Date of earliest event reported): April 21, 2006

                               CYTOGEN CORPORATION
               (Exact Name of Registrant as Specified in Charter)

          Delaware                     000-14879                22-2322400
----------------------------   ------------------------   ----------------------
(State or Other Jurisdiction   (Commission File Number)      (I.R.S. Employer
      of Incorporation)                                     Identification No.)

650 College Road East, CN 5308, Suite 3100, Princeton, NJ          08540
---------------------------------------------------------   --------------------
        (Address of Principal Executive Offices)                 (Zip Code)

       Registrant's telephone number, including area code: (609) 750-8200

          (Former Name or Former Address, if Changed Since Last Report)

     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_|  Written communications  pursuant to Rule 425 under the  Securities Act
(17 CFR 230.425)

     |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
Exchange Act (17 CFR 240.14d-2(b))

     |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
Exchange Act (17 CFR 240.13e-4(c))


     On  April  21,   2006,   Cytogen   Corporation   ("Cytogen")   and  Savient
Pharmaceuticals,  Inc.  ("Savient")  announced the  execution of a  distribution
agreement   granting  Cytogen   exclusive   marketing  rights  for  SOLTAMOX(TM)
(tamoxifen  citrate)  in the United  States.  SOLTAMOX,  a  cytostatic  estrogen
receptor  antagonist,  is the first oral liquid hormonal therapy approved in the
U.S.  It is  indicated  for the  treatment  of  breast  cancer in  adjuvant  and
metastatic settings and to reduce the risk of breast cancer in women with ductal
carcinoma in situ (DCIS) or with high risk of breast cancer.

     Under the terms of the final  transaction,  Cytogen paid Savient an upfront
licensing  fee of $2  million  and will pay  additional  contingent  sales-based
milestone  payments  of up to a total of $4 million  to  Savient  and its wholly
owned  subsidiary,  Rosemont  Pharmaceuticals  Ltd  ("Rosemont").   Savient  and
Rosemont will also receive royalties on net sales of SOLTAMOX

     Additionally, Cytogen has entered into a supply agreement with Rosemont for
the  manufacture  and supply of  SOLTAMOX.  Cytogen  expects to launch  SOLTAMOX
during the third quarter of 2006.

     Attached hereto and  incorporated by reference  herein as Exhibit 99.1 is a
copy of the related press release of Cytogen and Savient,  dated April 24, 2006.
A copy of the  Exclusive  Distribution  Agreement  and the  Manufacture & Supply
Agreement will be filed as exhibits to Cytogen's  upcoming  quarterly  Report on
Form 10-Q for the quarter ended March 31, 2006.


(c) Exhibits.

      Exhibit No.      Description
      -----------      -----------

         99.1          Press Release of Cytogen and Savient dated April 24, 2006


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                        CYTOGEN CORPORATION

                                        By:/s/ Michael D. Becker
                                           Michael D. Becker
                                           President and Chief Executive Officer

Dated:   April 26, 2006

                                  EXHIBIT INDEX

      Exhibit No.      Description
      -----------      -----------

          99.1         Press Release of Cytogen and Savient dated April 24, 2006